Prime Medicine (PRME) announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. Prior to joining Prime Medicine, Dr. Reine was Chief Financial Officer at Foghorn Therapeutics (FHTX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRME:
- Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
- Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Prime Medicine price target lowered by $6 at Morgan Stanley, here’s why
- Prime Medicine initiated with neutral view at Citi, here’s why
- Prime Medicine to Present at Upcoming Investor Conferences